New Study Alert!
Read our latest three-article study on groundbreaking insights from pharmacist-led interventions.
The multifaceted TRHC Research & Development Pillar includes contributions from numerous areas of expertise and research collaborators within the TRHC Precision Pharmacotherapy Research & Development Institute (PPRDI), Office of Translational Research and Residency Programs (OTRRP), and Office of Healthcare Analytics. The success of the Research & Development Pillar relies on an ever-evolving contemplation of work from experienced clinical pharmacists, clinical research scientists, pharmaceutical scientists, drug information specialists, data scientists, data analysts, software engineers, and software developers. These research specialists serve as subject matter experts and serve in more than 45 leadership roles in professional healthcare organizations.
Together, under the leadership of Chief Scientific Officer, Dr. Jacques Turgeon, the Research & Development Pillar consistently strives to innovate and redefine the science of medication safety to optimize medication use. The Research & Development Pillar is committed to the development of proprietary products, validation, and recognition by scientific and regulatory communities, improving patient outcomes and reducing preventable healthcare utilization and costs. To date, TRHC R&D has authored 118 original research articles, 14 case reports, 10 editorial pieces, 10 reviews, six commentaries, three clinical trials, two clinical guidelines, two mini-reviews, three systematic reviews, one book chapter, and three white papers.
Thus far in 2021, the Research & Development Pillar has 34 active research projects, 40 peer-reviewed publications in well-renowned journals, and seven manuscripts and book chapters accepted for publication. The Research & Development Pillar has received grant funding from both the Health Resources and Services Administration and the National Institute of Health (NIH), with two additional research grants under review with NIH.